Our clinical evidence shows a mean reduction of 1.7 to 2.0 point A1C drop for individuals living with type 2 diabetes who used BlueStar.
Our digital health solutions are changing the face of chronic disease management, reducing costs, improving clinical outcomes, and creating hope and change for individuals living with chronic diseases.
While our current solution, BlueStar, is a robust, highly intelligent app focused on type 2 diabetes, we are also pursuing digital solutions in other therapeutic areas.
Designed with clinical outcomes in mind
Includes insulin bolus dose calculator and requires Rx
More focused on tracking and sharing data
LifeScan Inc., one of the Johnson & Johnson Diabetes Care Companies (JJDCC) and a world leader in blood glucose monitoring, partnered to deliver a best-in-class digital health solution for type 2 diabetes. The OneTouch Verio Flex® blood glucose monitoring system with built-in Bluetooth® Smart Technology and the OneTouch Reveal digital system now wirelessly integrates with the clinically validated diabetes management platform, BlueStar®.
Cleared by the U.S. Food and Drug Administration (FDA), this combined offering seeks to create a comprehensive, data-driven and payer-reimbursed program for type 2 diabetes management. The partnership highlights LifeScan’s commitment to creating an integrated, connected experience for people with diabetes and value for health care providers.
Samsung Electronics, multinational electronics leader has entered a joint commercial partnership agreement with WellDoc to deliver a best-in-class digital health solution for individuals living with diabetes. The companies will integrate WellDoc’s newly-released consumer diabetes health app, BlueStar® C, with the recently launched Samsung Health, a mobile one-stop shop for health and fitness, and with Samsung Gear, including smart watches and fitness trackers.
BlueStar C is the consumer version of WellDoc’s suite of diabetes products. Its feedback and messaging is driven by the same patented decision support engine and high-quality analytics as the company’s clinically-proven original BlueStar platform and shares many of the same key features of the company’s therapeutic product offerings, but with a distinct lifestyle focus.
Specifically, BlueStar C offers:
The American Association of Diabetes Educators (AADE), partnered to incorporate the “AADE Diabetes Education Curriculum: A Guide to Successful Self Management” in the BlueStar® digital therapeutic platform. The curriculum, built around the AADE7 Self-Care Behaviors™, focuses on the seven primary areas of self-management: Healthy Eating, Being Active, Monitoring, Taking Medication, Problem Solving, Reducing Risks and Healthy Coping.
This partnership marks the first time AADE, a professional membership organization comprised of healthcare professionals from multiple disciplines dedicated to improving diabetes care through innovative education, management and support, has partnered with an organization to provide its curriculum in a consumer-friendly digital format.
Human API, the fastest-growing health data platform, partnered to explore the unique integration of type 2 diabetes patient health data within the BlueStar digital therapeutic platform. Human API’s data platform will provide real-time access to comprehensive clinical patient data from its network of 15,000+ pharmacies, health systems and laboratories. The steady flow of data is shared within a highly secure environment that ensures protection of data and patient privacy.
This partnership allows the seamless integration of medication, medical history and laboratory data from multiple sources with a patient’s consent but without requiring direct patient input – further optimizing the user experience and helping patients and their physicians make informed.
Ontario Telemedicine Network (OTN), a world leader in telemedicine along with Samsung Electronics in Ontario, Canada and WellDoc have launched an innovative demonstration program with BlueStar®. The goal of the program is to demonstrate the clinical and economic value of integrating a clinically proven self-management tool and lifestyle tracking into the type 2 diabetes treatment standard of care. The program includes a minimum of 300 people living with type 2 diabetes who will receive a prescription of BlueStar-S from their healthcare provider.
The combined offering, called BlueStar-S, will empower OTN participants to feel confident in their management of type 2 diabetes by also integrating personal fitness goals and health metric tracking with S Health®. The tool can be used to track eating, exercise, and sleep to help maintain a healthy lifestyle. Unlike other apps in the market, BlueStar® is unique in its ability to deliver a customized diabetes self-management program that is tailored to each patient based on his or her provider’s treatment plan.
WellDoc created digital health solutions long before smart phones were invented. We are the first digital health company to conduct randomized clinical trials that demonstrated significant clinical outcomes, which were published in peer-reviewed journals, and the first digital health company built on a life science business model.